BR102021007058B1 - Diagnóstico da covid-19 utilizando antígeno peptídico sintético proveniente da proteína do nucleocapsídeo - Google Patents
Diagnóstico da covid-19 utilizando antígeno peptídico sintético proveniente da proteína do nucleocapsídeo Download PDFInfo
- Publication number
- BR102021007058B1 BR102021007058B1 BR102021007058-7A BR102021007058A BR102021007058B1 BR 102021007058 B1 BR102021007058 B1 BR 102021007058B1 BR 102021007058 A BR102021007058 A BR 102021007058A BR 102021007058 B1 BR102021007058 B1 BR 102021007058B1
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- antigen
- solution
- antibodies
- covid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 63
- 239000000427 antigen Substances 0.000 title claims abstract description 52
- 108091007433 antigens Proteins 0.000 title claims abstract description 52
- 102000036639 antigens Human genes 0.000 title claims abstract description 52
- 238000003745 diagnosis Methods 0.000 title claims abstract description 24
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 13
- 108090001074 Nucleocapsid Proteins Proteins 0.000 title abstract description 3
- 238000012360 testing method Methods 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 23
- 238000002965 ELISA Methods 0.000 claims abstract description 22
- 108010091867 peptide P Proteins 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 108090000790 Enzymes Proteins 0.000 claims abstract description 10
- 102000004190 Enzymes Human genes 0.000 claims abstract description 10
- 238000003018 immunoassay Methods 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 238000011534 incubation Methods 0.000 claims description 16
- 235000018102 proteins Nutrition 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 10
- 239000012895 dilution Substances 0.000 claims description 10
- 238000010790 dilution Methods 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 239000000523 sample Substances 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 239000012089 stop solution Substances 0.000 claims description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 7
- 230000000903 blocking effect Effects 0.000 claims description 7
- 229940098773 bovine serum albumin Drugs 0.000 claims description 7
- 238000011161 development Methods 0.000 claims description 7
- 229940072221 immunoglobulins Drugs 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 239000013641 positive control Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000013060 biological fluid Substances 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 239000013642 negative control Substances 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 210000001138 tear Anatomy 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 239000003593 chromogenic compound Substances 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- -1 polypropylene Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000001143 conditioned effect Effects 0.000 claims 1
- 238000000151 deposition Methods 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000010324 immunological assay Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 19
- 230000035945 sensitivity Effects 0.000 abstract description 12
- 238000009007 Diagnostic Kit Methods 0.000 abstract description 8
- 230000003993 interaction Effects 0.000 abstract description 6
- 108091006197 SARS-CoV-2 Nucleocapsid Protein Proteins 0.000 abstract description 4
- 238000010200 validation analysis Methods 0.000 abstract description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 15
- 241000711573 Coronaviridae Species 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 230000000405 serological effect Effects 0.000 description 12
- 238000012286 ELISA Assay Methods 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 11
- 239000004033 plastic Substances 0.000 description 9
- 101710141454 Nucleoprotein Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 229940096437 Protein S Drugs 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000009589 serological test Methods 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000037029 cross reaction Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000013882 gravy Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 108010066124 Protein S Proteins 0.000 description 2
- 102000029301 Protein S Human genes 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108700002099 Coronavirus Nucleocapsid Proteins Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101710151619 Replicase polyprotein 1ab Proteins 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- NYNRGZULARUZCC-UHFFFAOYSA-N [4-(4-azaniumyl-3,5-dimethylphenyl)-2,6-dimethylphenyl]azanium;dichloride Chemical compound Cl.Cl.CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 NYNRGZULARUZCC-UHFFFAOYSA-N 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102021007058-7A BR102021007058B1 (pt) | 2021-04-14 | 2021-04-14 | Diagnóstico da covid-19 utilizando antígeno peptídico sintético proveniente da proteína do nucleocapsídeo |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102021007058-7A BR102021007058B1 (pt) | 2021-04-14 | 2021-04-14 | Diagnóstico da covid-19 utilizando antígeno peptídico sintético proveniente da proteína do nucleocapsídeo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR102021007058A2 BR102021007058A2 (sl) | 2021-11-23 |
| BR102021007058B1 true BR102021007058B1 (pt) | 2022-08-09 |
Family
ID=83594578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR102021007058-7A BR102021007058B1 (pt) | 2021-04-14 | 2021-04-14 | Diagnóstico da covid-19 utilizando antígeno peptídico sintético proveniente da proteína do nucleocapsídeo |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BR102021007058B1 (sl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112946294B (zh) * | 2020-04-02 | 2024-03-15 | 长春西诺生物科技有限公司 | 新型冠状病毒2019-nCoV抗体检测试纸条及其制备方法与应用 |
-
2021
- 2021-04-14 BR BR102021007058-7A patent/BR102021007058B1/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR102021007058A2 (sl) | 2021-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH04253998A (ja) | Ｃ型肝炎アッセイ | |
| US20070092938A1 (en) | Diagnostics for sars virus | |
| US20230358757A1 (en) | Antigen for 2019 novel coronavirus and detection use thereof | |
| CN112213497B (zh) | 检测新型冠状病毒s蛋白独特性抗体的多肽-elisa试剂盒 | |
| Cello et al. | Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides | |
| CN111978377B (zh) | Covid-19抗原、制备方法和应用 | |
| WO2005106483A1 (en) | Detection of west nile virus | |
| EP4298113A1 (en) | Peptides and their use in diagnosis of sars-cov-2 infection | |
| BR102021007058B1 (pt) | Diagnóstico da covid-19 utilizando antígeno peptídico sintético proveniente da proteína do nucleocapsídeo | |
| US20050100883A1 (en) | Peptide-based diagnostic reagents for SARS | |
| Rosati et al. | Characterization of the immunodominant cross-reacting epitope of visna maedi virus and caprine arthritis-encephalitis virus capsid antigen | |
| Goedhals et al. | Identification of human linear B-cell epitope sites on the envelope glycoproteins of Crimean-Congo haemorrhagic fever virus | |
| WO2008034297A1 (fr) | Procédé de détection d'anticorps dirigés contre une série de protéines virales d'immunodéficience humaine | |
| CN105510580A (zh) | 一种检测发热伴血小板减少综合征病毒核衣壳蛋白特异性抗体的多肽-酶联免疫吸附试剂盒 | |
| WO2022136624A1 (en) | African swine fever diva immunoassay | |
| TW201337268A (zh) | 一種偵測ｃ型肝炎病毒感染之方法 | |
| US20050214748A1 (en) | Peptide-based diagnostic reagents for SARS | |
| BR102020024390B1 (pt) | Peptídeo sintético p.sc2.s.132 para kit elisa de avidez no diagnóstico de covid-19 | |
| BR102020024403B1 (pt) | Antígenos peptídeos sintéticos para o diagnóstico do sars-cov-2 | |
| RU2776295C1 (ru) | Способ выявления заражения людей и животных SARS CoV2 и диагностический набор для осуществления способа | |
| KR910007962A (ko) | Hiv 관련 펩티드 | |
| BR102020024378B1 (pt) | Antígeno peptídeo sintético p.sc2.s.309 aplicado em kit e método elisa para diagnóstico sorológico de covid-19 | |
| SE470074B (sv) | Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider | |
| BR102020024380B1 (pt) | Peptídeo sintético p.sc2.s.129 para imunodetecção de anticorpos igm, iga e igg contra covid-19 | |
| Samuelson et al. | Enterovirus IgG ELISA using synthetic peptides as antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03B | Publication of an application: publication anticipated [chapter 3.2 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/04/2021, OBSERVADAS AS CONDICOES LEGAIS |
|
| B22L | Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi) |
Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE, EM 14/04/2041; 3) CONDICOES DE PAGAMENTO: ANUAL EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE ?KNOW-HOW?: SIM; 5) ASSISTENCIA TECNICA: NAO. |
|
| B22L | Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi) |
Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE, EM 14/04/2041; 3) CONDICOES DE PAGAMENTO: ANUAL EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE ?KNOW-HOW?: SIM; 5) ASSISTENCIA TECNICA: NAO. - OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR = NO ACESSO RAPIDO = BUSCA WEB = PATENTE. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI E USE LOGIN E SENHA. |
|
| B22L | Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi) |
Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE, EM 14/04/2041; 3) CONDICOES DE PAGAMENTO: ANUAL EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE KNOW-HOW: SIM; 5) ASSISTENCIA TECNICA: NAO. --- OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR - NO ACESSO RAPIDO = BUSCA DE PROCESSOS = FACA LOGIN COM SENHA OU TECLE CONTINUAR = PATENTE = DIGITE O NUMERO DO PROCESSO = PESQUISAR. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI. |
|
| B22L | Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi) |
Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE, EM 14/04/2041; 3) CONDICOES DE PAGAMENTO: ANUAL EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE KNOW-HOW: SIM; 5) ASSISTENCIA TECNICA: NAO. --- OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR - NO ACESSO RAPIDO = BUSCA DE PROCESSOS = FACA LOGIN COM SENHA OU TECLE CONTINUAR = PATENTE = DIGITE O NUMERO DO PROCESSO = PESQUISAR. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI. |